Kumar N B, Kazi A, Smith T, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment[J]. Curr Treat Options Oncol, 2010, 11(3/4): 107-117. ？ [2]Tisdale M J. Mechanisms of cancer cachexia[J]. Physiol Rev, 2009, 89(2): 381-410. ？ [3]Tsoli M, Robertson G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem[J]. Trends Endocrinol Metab, 2013, 24(4): 174-183. ？ [4]Julienne C M, Dumas J F, Goupille C, et al. Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency[J]. J Cachexia Sarcopenia Muscle, 2012, 3(4): 265-275. ？ [5]Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia[J]. Nat Rev Clin Oncol, 2013, 10(2): 90-99. [6]王强, 郑日勇, 彭旭东, 等. Carfilzomib缓解肿瘤恶病质骨骼肌消耗及其分子机制[J]. 第三军医大学学报, 2014, 36(20): 2113-2117.？ [7]Fearon K, Strasser F, Anker S D, et al. Definition and classification of cancer cachexia: an international consensus[J]. Lancet Oncol, 2011, 12(5): 489-495. ？ [8]Johns N, Stephens N A, Fearon K C. Muscle wasting in cancer [J]. Int J Biochem Cell Biol, 2013, 45(10): 2215-2229. ？ [9]Wang X N, Zhang L, Mitch W E, et al. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity[J]. J Biol Chem, 2010, 285(28): 21249-21257. [10]Workeneh B T, Mitch W E. Review of muscle wasting associated with chronic kidney disease[J]. Am J Clin Nutr, 2010, 91(4): 1128S-1132S. ？ [11]Furuno K, Goldberg A L. The activation of protein degradation in muscle by Ca？？2+？ or muscle injury does not involve a lysosomal mechanism[J]. Biochem J, 1986, 237(3): 859-864. ？ [12]Zhang L, Tang H , Kou Y, et al. MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia[J]. J Cancer Res Clin Oncol, 2013, 139(7): 1105-1115. ？ [13]Khan M L, Stewart A K. Carfilzomib: a novel second-generation proteasome inhibitor[J]. Future Oncol, 2011, 7(5): 607-612. ？ [14]Jakubowiak A J. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview[J]. Cancer Treat Rev, 2014, 40(6): 781-790. ？ [15]Mansour M A, Aljoufi M A, Al-Hosaini K, et al. Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma[J]. Chem Biol Interact, 2014, 215: 17-24. ？ [16]Teng B T, Tam E W, Benzie I F, et al. Protective effect of Caspase inhibition on compression-induced muscle damage[J]. J Physiol, 2011, 589(Pt 13): 3349-3369. ？ [17]Stratos I, Li Z D, Rotter R, et al. Inhibition of Caspase mediated apoptosis restores muscle function after crush injury in rat skeletal muscle[J]. Apoptosis, 2012, 17(3): 269-277. ？ [18]Segura I, Serrano A, De-Buitrago G G, et al. Inhibition of programmed cell death impairs ？in vitro？ vascular-like structure formation and reduces ？in vivo？ angiogenesis[J]. FASEB J, 2002, 16(8): 833-841.
[2]
王强,郑曰勇,彭旭东,等.Carfilzomib缓解肿瘤恶病质骨骼肌消耗及其分子机制[J].第三军医大学学报,2014,36(20):2113. Wang Qiang,Zheng Yueyong,Peng Xudong,et al.Carfilzomib ameliorates skeletal muscle consumption in mice with cancer cachexia and its molecular mechanism[J].J Third Mil Med Univ,2014,36(22):2113.
